Cancer News and Research

Latest Cancer News and Research

IMRT associated with reduced toxicities when compared with standard whole breast irradiation

Breast cancer patients treated with intensity modulated radiation therapy (IMRT) instead of standard whole breast irradiation (WBI) have a lower incidence of acute or chronic toxicities, according to a study in Practical Radiation Oncology (PRO), the official clinical practice journal of the American Society for Radiation Oncology (ASTRO).

29 Mar 2012

EpiCept to receive $0.97M in public offering

EpiCept Corporation announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 1,065 shares of its new Series B 0% Convertible Preferred Stock at $1,000 per share, which are convertible into an aggregate of approximately 6.3 million shares of its common stock, and five-year warrants to purchase up to approximately 3.1 million shares of its common stock at an exercise price of $0.17 per share that are immediately exercisable.

29 Mar 2012

Researchers profile genetic changes in cancer with drug sensitivity

In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalised approach to cancer treatments. The study is published in Nature on Thursday 29 March 2012.

29 Mar 2012

Scientists explore number of strategies to prevent anesthesia-induced injury in infants

Recent clinical studies have shown that general anesthesia can be harmful to infants, presenting a dilemma for both doctors and parents. But new research at Wake Forest Baptist Medical Center may point the way to treatment options that protect very young children against the adverse effects of anesthesia.

29 Mar 2012

EU's Safety Evaluation Ultimately Replacing Animal Testing initiative tests Roche's xCELLigence system

Roche's xCELLigence RTCA System is being used in the European Union's SEURAT (Safety Evaluation Ultimately Replacing Animal Testing) initiative to run five years from 2011 to 2016.

From Roche Sequencing and Life Science 29 Mar 2012

NEJM publishes results from Amgen's brodalumab Phase 2 trial on plaque psoriasis

Amgen announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine.

29 Mar 2012

MESO-1 device can help in diagnosis and treatment of cancer

A new device designed to more effectively produce DNA samples for genetic testing from slide-mounted tissue samples is better equipped than most models on the market to help in the diagnosis and treatment of cancer.

29 Mar 2012

Nature journal publishes first volume of Cancer Cell Line Encyclopedia

The goal of cancer treatment is to match the right drug to the right target in the right patient. But before such "personalized" drugs can be developed, more knowledge is needed about specific genomic alterations in cancers and their sensitivity to potential therapeutic agents.

29 Mar 2012

Rates of cancer diagnoses and deaths continue to decline in the U.S.

A report from the nation's leading cancer organizations shows rates of death in the United States from all cancers for men and women continued to decline between 2004 and 2008. The findings come from the latest Annual Report to the Nation on the Status of Cancer.

29 Mar 2012

MiR-375 regulates IL-13-induced changes in allergic diseases

Researchers have taken a critical step in understanding how allergic reactions occur after identifying a genetic signature for regulation of a key immune hormone, interleukin (IL-13).

29 Mar 2012

Strand Diagnostics to receive $30 million in funding from NantWorks

Strand Diagnostics, LLC, maker of the know error system, and NantWorks, LLC announced that they have entered into an agreement whereby Strand will receive up to $30 million in funding from NantWorks, LLC over the next 3 years.

29 Mar 2012

Spherix 2011 net loss decreases to $3.5 million

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today reported financial results for the year ended December 31, 2011, and recent and upcoming business highlights.

29 Mar 2012

Protein's location in a cell affects impact on disease

If the fight against breast cancer were a criminal investigation, then the proteins survivin, HDAC6, CBP, and CRM1 would be among the shadier figures. In that vein, a study to be published in the March 30 Journal of Biological Chemistry is the police report that reveals a key moment for keeping cancer cells alive: survivin's jailbreak from the nucleus, aided and abetted by the other proteins.

29 Mar 2012

Scientists uncover new layer of information in the genetic code

A hidden and never before recognized layer of information in the genetic code has been uncovered by a team of scientists at the University of California, San Francisco (UCSF) thanks to a technique developed at UCSF called ribosome profiling, which enables the measurement of gene activity inside living cells - including the speed with which proteins are made.

29 Mar 2012

Chromosomal abnormality in children with ependymoma linked with poorer chance of survival

A chromosomal abnormality in children with a deadly form of brain cancer is linked with a poorer chance of survival, clinician scientists at The University of Nottingham have discovered.

29 Mar 2012

Clovis commences CO-1686 Phase I/II study in NSCLC

Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.

29 Mar 2012

Inhibitory control test and lactulose for MHE saves more than $3 million over 5 years

A late stage liver condition, known as minimal hepatic encephalopathy (MHE), is associated with impaired driving skills and greater risk of motor vehicle accidents. Cost analysis of management strategies for detection and treatment of MHE are published in the April issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

29 Mar 2012

Merrimack prices initial public offering of 14,300,000 shares of common stock

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.

29 Mar 2012

Aspirin lowers risk for cancers: Meta analysis

Aspirin has multiple benefits. It is a painkiller whose origins can be traced to Hippocrates, reduces the chances of developing or dying from cancer earlier than previously thought and also prevents tumors from spreading, studies show.

28 Mar 2012

Potential new therapy that kills cancer cells selectively

Researchers have made a drug that helps the immune system to break down cancerous tumors. It has worked on breast, bowel, prostate, ovarian, brain, bladder and liver cancers, while previous studies show it can also be used to fight some blood cancers. If given early, the drug could even be a cure, researchers say.

28 Mar 2012

Cancer News and Research

Latest Cancer News and Research

IMRT associated with reduced toxicities when compared with standard whole breast irradiation

EpiCept to receive $0.97M in public offering

Researchers profile genetic changes in cancer with drug sensitivity

Scientists explore number of strategies to prevent anesthesia-induced injury in infants

EU's Safety Evaluation Ultimately Replacing Animal Testing initiative tests Roche's xCELLigence system

NEJM publishes results from Amgen's brodalumab Phase 2 trial on plaque psoriasis

MESO-1 device can help in diagnosis and treatment of cancer

Nature journal publishes first volume of Cancer Cell Line Encyclopedia

Rates of cancer diagnoses and deaths continue to decline in the U.S.

MiR-375 regulates IL-13-induced changes in allergic diseases

Strand Diagnostics to receive $30 million in funding from NantWorks

Spherix 2011 net loss decreases to $3.5 million

Protein's location in a cell affects impact on disease

Scientists uncover new layer of information in the genetic code

Chromosomal abnormality in children with ependymoma linked with poorer chance of survival

Clovis commences CO-1686 Phase I/II study in NSCLC

Inhibitory control test and lactulose for MHE saves more than $3 million over 5 years

Merrimack prices initial public offering of 14,300,000 shares of common stock

Aspirin lowers risk for cancers: Meta analysis

Potential new therapy that kills cancer cells selectively

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in